Biogen

Biogen

A biotechnology company with a focus on treatments for neurological and neurodegenerative diseases. It was founded in 1978 and has headquarters in Cambridge, Massachusetts.

Biogen is a United States-based company in the pharmaceutical industry that researches, develops, and delivers therapies for people living with serious neurological and neurodegenerative diseases. It has other locations world wide including Denmark and Switzerland. It has the stated goal of delivering therapies for its patients as well as investing in areas of highest return to deliver long-term value to its stockholders.

Products

The company manufactures therapies and medicines for diseases such as Parkinson's, Spinal Muscular Atrophy, and Multiple Sclerosis. It also researches solutions for other diseases such as Lupus, Epilepsy, and Schizophrenia. Biogen's drug aducanumab is under review by the Federal Drug Administration and has shown evidence of having the capability of reducing medical conditions that can cause Alzheimer's.

In March 2020, Biogen partnered with Vir to research and manufacture therapies for COVID-19. With the antibody development and manufacturing pact made between the two companies, Biogen would play the role of manufacturing and Vir has researched and developed the antibodies.

Timeline

People

Name
Role
LinkedIn

Alphonse Galdes, Ph.D.

Executive Vice President

Chirfi Guindo

Executive Vice President

Ginger Gregory, Ph.D.

Executive Vice President

Jeffrey Capello

Executive Vice President

Michel Vounatsos

CEO

Susan Alexander

Executive Vice President

Executive Vice President

Further reading

Title
Author
Link
Type
Date

Biogen signs on to manufacture clinical supplies for Vir's COVID-19 antibodies

Eric Sagonowsky

Web

March 12, 2020

Documentaries, videos and podcasts

Title
Date
Link

Join Biogen's virtual reality experience at ECTRIMS in Stockholm

August 28, 2019

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Angus Liu
February 18, 2021
FierceBiotech
In 2018, a collaboration between Washington University and Denali Therapeutics resulted in an antibody drug that showed promise as a potential Alzheimer's therapy. Now, the team has returned with mouse data suggesting the drug might be a safer option than Biogen's much-hyped aducanumab.
Spherix Global Insights
February 12, 2021
www.prnewswire.com:443
/PRNewswire/ -- Ten months after the doors closed in response to the COVID-19 pandemic, a survey of 266 US specialty physicians conducted by Spherix Global...
Spherix Global Insights
February 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- With the recent additions of Novartis' Mayzent, Bristol Myers Squibb's Zeposia, and Biogen's Vumerity to the multiple sclerosis (MS) market in...
Arcadia
February 5, 2021
www.prnewswire.com:443
/PRNewswire/ -- Arcadia, a monthly subscription service that connects renters and homeowners across the US to wind and solar energy through their utility...
Ben Adams
February 3, 2021
FierceBiotech
As Biogen hopes and prays for a (now delayed) FDA approval of its controversial Alzheimer's disease hopeful aducanumab, a key, closely watched pipeline asset has failed and been tossed out.
Allison DeAngelis
January 29, 2021
Business Insider
The FDA has extended its deadline to approve or reject Biogen's drug by three months. Analysts say continuing the deliberations is a good sign.
Research and Markets
January 29, 2021
www.prnewswire.com:443
/PRNewswire/ -- The "Global Autoinjectors Market By Type, By Application, By End Use, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been...
Ben Adams
January 29, 2021
FierceBiotech
Rip up the rulebooks: It's no longer investing 101, but investing 2021, where anything goes.
Andrew Dunn and Allison DeAngelis
January 15, 2021
Business Insider
Gene therapy biotechs were overshadowed and struggled, while a highly debated theory on treating Alzheimer's disease got a boost.
Conor Hale
January 12, 2021
FierceBiotech
Alongside hopes that it will soon have a new drug for Alzheimer's disease speeding to market, Biogen has announced a new research project with Apple to see whether the company's iPhones and smartwatches can help monitor users for declines in cognitive health.
Ben Adams
January 11, 2021
FierceBiotech
We're used to formal clothing expensive hotels and meeting venues that solitary confinement cells look spacious, with the offer of $20 coffees (if spending a minimum of $100), but this year, things are very different.
Ben Adams
January 11, 2021
FierceBiotech
Biogen's C-suite remains bullish that its controversial Alzheimer's disease drug aducanumab will be approved in the coming weeks, citing a rare glimmer of hope from a similar drug from Eli Lilly that posted broadly positive data today.
Nick Paul
January 11, 2021
FierceBiotech
Atalanta Therapeutics has broken cover with $110 million from a series A round and partnerships with Biogen and Genentech. The biotech secured the deals and funding on the strength of evidence it can durably silence genes in the brain.
Law Offices of Howard G. Smith
January 8, 2021
www.prnewswire.com:443
/PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming January 12, 2021 deadline to file a lead plaintiff motion in the case filed on...
The Law Offices of Frank R. Cruz, Los Angeles
January 6, 2021
www.prnewswire.com:443
/PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or...
Glancy Prongay & Murray LLP
January 4, 2021
www.prnewswire.com:443
/PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming January 12, 2021 deadline to file a lead plaintiff motion in the class...
Law Offices of Howard G. Smith
December 22, 2020
www.prnewswire.com:443
/PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming January 12, 2021 deadline to file a lead plaintiff motion in the case filed on...
LogicBio Therapeutics, Inc.
December 22, 2020
www.prnewswire.com:443
/PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced the appointment of Cecilia Jones as the...
Guttman, Buschner & Brooks PLLC
December 17, 2020
www.prnewswire.com:443
/PRNewswire/ -- One of the world's largest pharmaceutical companies, Biogen, Inc., and a large specialty pharmacy, Advanced Care Scripts, Inc. (ACS), will pay...
Ben Adams
December 9, 2020
FierceBiotech
Lobbying group Public Citizen is crying foul on an "inappropriate close collaboration" between the FDA and Biogen surrounding the pharma's controversial Alzheimer's disease drug aducanumab and the related FDA advisory committee documents.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.